Mandate

Vinge advises Capio in connection with the acquisition of the Nova clinics

February 26, 2018 M&A

Vinge has advised Capio, which is listed on Nasdaq Stockholm, in connection with the acquisition of the shares in the Nova clinics.

The Nova clinics primarily conduct healthcare operations at eight clinics in the southeast of Skåne and have certain operations within occupational health service and dental service. In 2017, the Nova clinics had a turnover of approximately MSEK 245 and had approximately 45 000 listed patients. The purchase price mechanism, which is based on Enterprise Value, amounts to MSEK 88. The acquisition is conditional upon the Swedish Competition Authority’s and Region Skåne’s approval.

Vinge’s team consisted of Anders Strid, Frida Bäckegren (project manager), Gabriella Fossum (LOU), Rebecka Maltenius (commercial property law), Lina André (employment law), Camilla Andersson (company registration assistant) as well as Pär Remenlid and Nils Alvång (both competition law).

Related

Vinge advises Axcel and Sanviva on the acquisitions of DermaCura and YourRad

Vinge has advised Axcel Elevate I and Sanviva in connection with the acquisitions of DermaCura and YourRad.
September 07, 2026

Vinge advises Revivo Group on the acquisition of Premator

Revivo Group AB has acquired all the shares in Premator AB, the parent company of a group operating in the field of advanced surface treatment with extensive experience in shot blasting, anti-corrosion painting and related services. Operations are conducted in Sweden, Norway and Denmark.
September 03, 2026

Vinge advises the sellers on the sale of Nextory to Bonnier Books

Vinge has acted as legal adviser to the sellers in connection with Bonnier Books’ acquisition of Nextory, one of Europe’s leading streaming services for audiobooks and e-books. Bonnier Books is acquiring all shares in Nextory, and the transaction comprises Nextory’s operations in Sweden and internationally. The acquisition is a cash transaction and the parties have agreed not to disclose the purchase price. The transaction is subject to customary regulatory approvals.
September 02, 2026